Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation.

Scientists at St. Jude Children's Research Hospital, the National Center for Genomic Analysis and the University of Adelaide ...

The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to ...

Oregon will increase access to affordable, lifesaving cell and gene therapies for individuals on the Oregon Health Plan (OHP) ...

CAR-T cells are specialized immune cells genetically modified to recognize and attack cancer cells. Researchers at Nagoya ...

RNA gene scissors (CRISPR-Cas13) are gaining significant attention as a next-generation gene therapy with fewer side effects.

Facility expansions and over 5,800 CGT/ATMP batches manufactured underscore Cellex's strength as a trusted full-service CDMO in Europe. COLOGNE, Germany, June 10, 2025 /PRNewswire/ -- Cellex ...

Cellex Cell Professionals (Cellex), a full-service Contract Development and Manufacturing Organization (CDMO) with 10+ years of experience in Cell & Gene Therapy (CGT), announces facility expansion ...

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that ...

Glioblastoma has been deadly and hard to treat, but researchers say they’ve made progress with bivalent CAR T-cell therapy ...